Expanded View Figures

Figure EV1. Effects of incubation time upon proteolytic cleavage.

(**A**) The plots show peptide intensities after proteolytic cleavage for 1 min to 5 min, comparing samples with 100 µM PK with and without electroporation. Each data point represents a single peptide; half-tryptic peptides are shown in orange and fully tryptic peptides are shown in blue. The shaded gray region marks significance levels (FC > 1.5, q-value < 0.05, $n = 5$ technical replicates). (**B**) The plot shows the fraction of half-tryptic peptides under the indicated conditions after in-cell LiP-MS. (**C**) Changing peptides per protein after 90 min arsenite treatment compared to untreated cells (data in Figure **B**). Peptides due to PK cleavages upon PK electroporation (data in Fig. 1H) are in blue. (**D**, **E**) The number of detected peptides per protein (**D**) and overall sequence coverage (**E**) at optimized in-cell LiP-MS conditions (2 min +/− EP). (**F**) The plot shows peptide intensities after proteolytic cleavage for 2 min, comparing samples with 100 µM PK to untreated cells (both without electroporation). Each data point represents a single peptide; half-tryptic peptides are shown in orange and fully tryptic peptides are shown in blue. The shaded gray region marks significance levels (FC > 1.5, q-value < 0.05, $n = 5$ technical replicates). (**G**) Gene ontology enrichment analysis of proteins with PK cleavages in (**F**) (p-value < 0.001). (**H**) Position of PK cleavages along the sequence of substrate proteins. The cleavage position is defined either by the position of the first amino acid in a peptide with an n-terminal HT end, or by the position +1 of the last amino acid in a peptide with a c-terminal HT end. Cleavage positions on proteins with more than 2 cleavages are shown in blue, and those with up to 2 cleavages are shown in orange. To generate technical replicates, cells were split into the indicated number of aliquots before treatment.


A
1 min +/- EP
2 min +/- EP
5 min +/- EP
- Log10 (p-value)
Log2 FC (Treated/Control)
6590 cleavage sites on 2299 proteins
7182 cleavage sites on 2367 proteins
6987 cleavage sites on 2341 proteins
Number of proteins
Cleavages per protein
B
% Half-tryptic peptides
Incubation time [min]
no PK
PK electroporated
PK not electroporated
C
+/- 90 min arsenite
Changing peptides per protein
PK cleavage upon EP
No
Yes
D
Peptides per protein
E
% Sequence coverage
F
2 min +/- PK
G
integral component of plasma membrane
cell surface
plasma membrane
extracellular space
focal adhesion
- Log10 (p-value)
H
Number of HT peptides
Cleavage position / Protein length [%]
Cleavages per protein
> 2
1 or 2


A
In-cell LiP-MS
Standard LiP-MS
Log2 (Intensity)
Condition
Control
Rapamycin
25
20
15
10
5
0
B
In-cell LiP-MS
Standard LiP-MS
Number of proteins
4188
4006
C
Number of peptides
73286
54223
D
Peptides per protein
E
Peptide length
F
100 nM
250 nM
Time (min)
p-S6S240-244
S6
mTORC1 activity
p-AKTS473
AKT
mTORC2 activity

Figure EV2. Rapamycin treatment.

(**A–E**) In-cell LiP-MS of HEK293 cells treated with 20 μM rapamycin compared to DMSO control; standard LiP-MS in a native lysate of HEK293 cells treated with 10 nM rapamycin compared to DMSO control. Plots (**B–E**) show indicated quantities across both conditions (in-cell LiP-MS $n = 12$; standard LiP-MS $n = 8$ technical replicates). Error bars are shown in black. (**A**) Heatmap of peptide intensities (stripped sequence level). Colors above the heatmap correspond to the indicated conditions. (**B**) Number of detected proteins. (**C**) Number of detected peptides. (**D**) Overall sequence coverage considering peptides in both rapamycin treated and control samples (in-cell LiP-MS $n = 12$ replicates; standard LiP-MS $n = 8$ technical replicates). (**E**) Number of peptides with indicated length relative to total peptide intensity. Only peptides with up to 50 amino acids are shown. To generate technical replicates, cells were split into the indicated number of aliquots before treatment. (**F**) HEK293T cells were treated with rapamycin under the indicated conditions and probed for mTORC1 or mTORC2 activity using Western blots against the indicated phospho-proteins. The plots (right) show quantification of the Western blots on the left. Statistics were performed with two-way ANOVA on three biological replicates (*$p \leq 0.05$; **$p \leq 0.01$; ***$p \leq 0.001$). Each replicate was biologically independent, consisting of cells grown separately prior to treatment.


A
Cytosol
ρ = 0.74
Nucleus
ρ = 0.73
Mitochondrion
ρ = 0.65
Endoplasmic reticulum
ρ = 0.71
Golgi apparatus
ρ = 0.71
Cytoplasmic stress granule
ρ = 0.65
Log10 (In-cell LiP)
Log10 (Lysate LiP)
B
Cytosol
Nucleus
Mitochondrion
Endoplasmic reticulum
Golgi apparatus
Cytoplasmic stress granule
Number of peptides
Log10 (In-cell LiP) / Log10 (Lysate LiP)

◀ **Figure EV3. Organelle coverage in LiP-MS in cells.**

(**A**) Correlation of average peptide intensities in indicated organelles in HEK293 cells between LiP-MS in lysate and in cells after 5 min of DMSO treatment (in-cell LiP-MS $n = 6$ replicates; lysate LiP-MS $n = 4$ technical replicates); ρ indicates the Pearson correlation coefficient. Peptides in blue are mapping to proteins located at the indicated organelle based on gene ontology annotation in Spectronaut. Peptides from other organelles are colored gray. (**B**) Ratio of average peptide intensities in lysate and in-cell LiP-MS for indicated organelles. To generate technical replicates, cells were split into the indicated number of aliquots before treatment.



Figure EV4. Stress granule formation upon arsenite treatment.

(**A**) Comparison of HEK293 cells treated with sodium arsenite to untreated cells. Each data point represents a single protein. The shaded gray region marks significance levels (FC > 1.5, *p*-value < 0.05, $n = 6$ biological replicates). (**B**, **C**) Gene ontology enrichment analysis of proteins with peptide-level structural changes upon arsenite treatment (q-value < 0.01). (**B**) Molecular function. (**C**) Biological process. Each replicate was biologically independent, consisting of cells grown separately prior to treatment.


10 min
20 min
90 min
G3BP1
0 100 200 300 400
DDX17
0 200 400 600
ATXN2L
0 250 500 750 1000
IGF2BP1
0 100 200 300 400 500
DDX6
0 100 200 300 400
PABPC1
0 200 400 600
HNRNPA1
0 100 200 300
HNRNPA2B1
0 100 200 300
ELAVL1
0 100 200 300
DDX5
0 200 400 600
VCP
0 200 400 600 800
XRN2
0 250 500 750
PRRC2C
0 1000 2000
SFPQ
0 200 400 600
NONO
0 100 200 300 400
YBX3
0 100 200 300
IGF2BP1
0 100 200 300 400 500
PCBP2
0 100 200 300
DHX36
0 250 500 750 1000
SRSF1
0 50 100 150 200
EIF4A1
0 100 200 300 400
EIF4A3
0 100 200 300 400
EIF4G1
0 400 800 1200
EIF4G3
0 400 800 1200
EIF5
0 100 200 300 400
EIF5A
0 50 100 150
EIF2S2
0 100 200 300
EIF2S3
0 100 200 300 400
EEF2
0 200 400 600 800
EIF2B3
0 100 200 300 400
DDX3
0 200 400 600
EIF4E
0 50 100 150 200
FUS
0 100 200 300 400 500
CAPRIN1
0 200 400 600
FMR1
0 200 400 600

◀ **Figure EV5. Structural changes in stress granule proteins upon arsenite treatments.**

Proteins showing structural changes upon arsenite treatment. The barcode plots depict the protein sequence, blue regions are detected by mass spectrometry. Orange regions change significantly at the indicated time (FC > 1.5, q-value < 0.05, $n = 6$ biological replicates). Each replicate was biologically independent, consisting of cells grown separately prior to treatment.

